Autologous recovery is a major problem with busulfan as a marrow ablative agent in conditioning children for allogeneic BMT. Data suggest the average concentration of busulfan at steady state (Bu Css) is critical for successful engraftment. We prospectively evaluated busulfan pharmacokinetics in 31 children (age 0.6-18 years) with AML (n = 9), and non-malignant diseases (n = 22) receiving HLA-closely matched (sibling, parent, unrelated) donor grafts. Blood samples were obtained following dose 1 and 13 of a standard 16 dose, 4-day regimen. The busulfan dose varied from 14 to 20 mg/kg. Patients received cyclophosphamide 200-240 mg/kg; 22/31 received 80-90 mg/kg of ATG. Eight patients failed to engraft (26%). ATG did not appear to influence engraftment (P = 0.38). Bu Css levels Ͻ600 ng/ml correlated with autologous recovery/mixed chimerism (P = 0.018). There were no graft failures in patients with a Bu Css Ͼ600 ng/ml. A correlation between Bu Css levels and regimen-related toxicity (RRT) was not identified for grade 2 or higher toxicities, only 1/31 had a Bu Css Ͼ900 ng/ml. Our data support the use of pharmacokinetic monitoring of busulfan. Bone Marrow Transplantation (2000) 25, 925-930. Keywords: busulfan; children; bone marrow transplantation; cyclophosphamide; toxicity Busulfan is a potent myelotoxin that complements the lymphocyte toxicity of cyclophosphamide in preparative regimens for hematopoietic stem cell transplantation.
children exhibit average busulfan steady-state concentrations (Css) or an area under the curve (AUC) substantially less than do older children or adults. [7] [8] [9] The Css corresponds to the AUC over a dosing interval divided by the 6 h between doses. The AUC over a dosing interval is equal to the AUC from the time the first dose is ingested to infinity if no subsequent doses are taken. A Css of 900 ng/ml is equal to an AUC of 1350 m × min.
Few studies of the relationship between busulfan Css (Bu Css) or AUC and outcome of the busulfan/ cyclophosphamide preparative regimen have focused on children. Adults with CML have been shown to be at increased risk of relapse if Bu Css is low and exhibit less busulfan-related toxicity compared to patients with other diseases receiving similar treatment. 10, 11 Excessively low levels of busulfan have been related to graft rejection, while high levels have been related to severe toxicities. 12, 13 Of particular interest in children is the issue of graft rejection. Since cyclophosphamide is directly toxic to mature lymphocytes and busulfan is not, graft rejection has been thought to be due to inadequate dosing of cyclophosphamide. 1, 14 Thus, the relatively high incidence of graft rejection in children receiving a busulfan/cyclophosphamide preparative regimen has resulted in the use of higher doses of cyclophosphamide than are used in adults. ATG also has been added to the regimen in an attempt to gain additional immune suppression. However, graft rejection is still relatively frequent, even with total doses of cyclophosphamide as high as 200-240 mg/kg and ATG. We therefore sought to determine whether graft rejection was associated with low Bu Css in children receiving 14-20 mg/kg busulfan and 200-240 mg/kg cyclophosphamide, whether toxicities (primarily to the gastrointestinal (GI) mucosa, liver and lung) were associated with high busulfan levels and whether ATG facilitated engraftment in our patients who were conditioned with busulfan and cyclophosphamide.
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Methods
Patients and treatments
We prospectively evaluated busulfan pharmacokinetics in 38 pediatric patients (age 0.6 to 18 years) with AML (n = 14) and non-malignant diseases (n = 24) who were receiving HLA-matched or closely matched sibling (n = 28), parent (n = 3), or unrelated (n = 4) donor marrow grafts. Donor cell dose was approximately 5 × 10 8 per kilogram for all patients. Patient demographics are described in Table 1 . All patients enrolled in BMT protocols from May 1991 to April 1996 that included busulfan as a conditioning agent were eligible. Seven patients were excluded: two received autologous transplants, one received a syngeneic transplant, two received a T cell-depleted transplant, one received melphalan and one was excluded due to problems in obtaining samples. Parents of all patients provided informed consent for participation in this study which was approved by the Committee on Human Research at the University of California, San Francisco. Patients over 12 years of age also provided assent to participate.
Busulfan was administered as part of the BMT preparative regimen as the standard 16 dose, 4 day regimen begin- ning at 9 a.m. on the first day of conditioning. In the 31 patients evaluated, the total oral busulfan dose varied from 14 to 20 mg/kg. Busulfan was followed by cyclophosphamide administered i.v. at 50 to 60 mg/kg on 4 consecutive days (only one patient received a total dose of 240 mg/kg); 22/31 patients (71%) received a total dose of 80 to 90 mg/kg ATG (Table 1) . A compounded suspension of oral busulfan was administered through a nasogastric tube in children unable to reliably swallow tablets. All other patients received doses as commercially available 2 mg tablets. Patients were NPO for at least 1 h before and 1 h after busulfan administration. Graft-versus-host disease (GVHD) prophylaxis was methotrexate (MTX) (n = 1); cyclosporine (CsA) (n = 3); or a combination of CsA/MTX (n = 25), CsA/MTX/methylprednisolone (n = 3) or CsA/prednisone (n = 1). Phenytoin (PHT), dose adjusted to maintain therapeutic levels, was administered to nine patients (29%) as prophylaxis against busulfan-related seizures.
Samples and pharmacokinetic analysis
Blood samples were collected for analysis in heparinized tubes at times 0, 30, 60, 120, 180, 240, 300 and 360 min 927 following the first and thirteenth busulfan doses. Samples were stored on ice until the plasma was separated and frozen at −20°C until analysis. Specimens were sent on dry ice by overnight express mail for analysis by gas chromatography/mass spectrometry. Samples from the first 12 patients were assayed at the University of Minnesota. All remaining samples were assayed by the Fred Hutchinson Cancer Research Center (FHCRC). 15 Bu Css was calculated as previously described. 13 Data reported for Bu Css are the mean value for each patient.
Toxicity and rejection
Regimen-related toxicity (RRT) was evaluated using BMT criteria described by Bearman et al 16 during the first 28 days post transplant and assigned a grade of 1 to 4. Engraftment was defined as an absolute ANC Ͼ500 for 3 consecutive days with evidence of donor cells either by PCR for non-HLA DNA polymorphisms and/or in situ hybridization for X and Y chromosomes in sex-mismatched transplants. A quantitative estimate of engraftment (percent donor cells) was provided for sex-mismatched transplants. For non-HLA DNA assays, unique donor and recipient alleles were identified to assess full donor chimerism (sensitivity of 1-5%). For analysis, we included as 'engrafted' only those patients with 100% donor chimerism. Primary graft rejection was defined as no evidence of donor cells; secondary rejection was documented by initial evidence of donor engraftment followed by full autologous recovery. Engraftment was evaluated at 3 month intervals up to 1 year post BMT.
Statistical analysis
Average Bu Css between engrafted and non-engrafted patients was compared by Wilcoxon rank-sum test. The logistic regression model 17 was used to relate Bu Css, donor source, GVHD prophylaxis and other patient characteristics (weight, age, cyclophosphamide and ATG) to probability of engraftment or toxicity. Donor source and GVHD prophylaxis were analyzed with relation to engraftment using the Fisher exact test. A scatter plot smoother 18 was used to develop a model-free estimate on the average relationship between engraftment probability and Bu Css.
Results
Busulfan concentration and graft rejection
Busulfan concentration and transplant outcome are shown in Table 2 . The mean busulfan level was defined as the average of the first and second values when available. For subjects with only one value, the mean listed is that value. The population average of the mean blood levels was 528 ng/ml. The median was 473 ng/ml with a range of 157-2061 ng/ml. The subject with a single outlying value of 3543 ng/ml was included in statistical analysis but excluded from the curves shown in Figures 1 and 2 . Of patients who received ATG, 15/23 (65%) engrafted compared with 8/9
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The use of mean Bu Css as a predictor condenses two measurements into one. This may result in the loss of predictive information. For instance, a subject with the levels of 400 ng/ml and 800 mg/ml has the same average level as a subject with 550 ng/ml and 650 ng/ml, respectively. Such differences may have implications for the probability of engraftment. To examine this, we fitted the model to the 24 subjects with two blood level measurements. Two predictors were included in a logistic regression model; the average blood level and the difference between the average and the minimum blood level. The model found strong predictive value in the former but no predictive information in the latter variable. Hence, it appears that the probability of engraftment depends on Bu Css rather than the minimum or maximum exposure.
The incidence of graft rejection in relation to busulfan concentration and source of graft is described in Table 3 . Of the 31 evaluable patients, eight failed to engraft (two were mixed chimeras), giving a 74% successful full donor engraftment rate. Bu Css levels Ͻ600 ng/ml significantly correlated with autologous recovery/mixed chimerism according to the Wilcoxon rank-sum test (P = 0.018). There were no graft failures in the eight patients with Bu Css Ͼ600 ng/ml. The logistic regression model was used to fit a dose-response relationship between average Bu Css and probability of engraftment in 30 subjects (Figure 1 ). An alternative approach was to use a model-free scatterplot smoother (Lowess) to develop a dose response relationship (Figure 1 ). The logistic model predicts that the Bu Css that ensures a 90% chance of engraftment is 639 ng/ml and that 762 ng/ml is required to ensure a 95% chance of engraftment. The Lowess smoother predicts that 90% of subjects will successfully engraft with an average Bu Css of 532 ng/ml and 95% of subjects will be engrafted successfully with a Bu Css of 569 ng/ml. While the data show that all eight subjects who were evaluated with levels greater than 600 ng/ml successfully engrafted, we do not have enough data to clearly identify the threshold Bu Css at which engraftment is ensured. Of the eight patients who failed to engraft, seven had genetic disorders and one had AML. While there does not appear to be a correlation between diagnosis and engraftment, our numbers are too small to reach a conclusion.
Busulfan concentration and toxicity
All 38 patients were included in the toxicity analysis (Table  4) . A high percentage of patients (36/38) experienced grade 1 GI toxicity (diarrhea) which may have been in part caused by GI antimicrobial decontamination with oral vancomycin and gentamicin. Grade 1 or 2 hepatic toxicity was observed in 30 patients (79%) and 14 (37%) experienced grade 2 or less renal toxicity. There were four patients (11%) with seizures (grade 3 neurotoxicity) attributed to the conditioning regimen; none of these children received seizure prophylaxis. Since seizures are felt to be a preventable toxicity, these patients were not included in the evaluation of Bu Css and risk of toxicity. There were two cases (5%) of 0  209  624  503  563  2  stomatitis  1  214  673  648  660  3  CNS  1  215  549  594  571  2  renal/hepatic  0  218  574  321  448  2  hepatic  0  223  595  894  745  3  CNS  1  229  497  360  429  2  hepatic  0  232  352  426  389  1  hepatic/GI  0  239  581  557  569  2  renal  1  241  1011  658  835  1 hemorrhagic cystitis (grade 3 bladder toxicity) and one case of fatal VOD (grade 4 hepatic toxicity).
The logistic regression model was again employed to relate the risk of toxicity to Bu Css in 30 patients. The data show virtually no dose-response relationship between blood level and risk of grade 2 or higher toxicity. Figure  2 shows the fit of the model to the risk of a grade 3 or higher toxicity. The data show that only a single patient with levels Ͻ600 ng/ml had a grade 3 or higher toxicity. Among the seven patients evaluated with blood levels у600 ng/ml, three (42%) developed a grade 3 or higher toxicity, two of which were seizures. The logistic model predicts that this probability may vary considerably over Table 4 Regimen-related toxicity 
Discussion
The major findings of this investigation are that engraftment following hematopoietic stem cell transplantation using a busulfan and cyclophosphamide preparative regimen correlates with Bu Css while the incidence of regimen-related toxicity did not. Relationships between Bu Css and graft rejection have been reported previously. Based on earlier work, thresholds for rejection appear to be 200 ng/ml for HLA matched and partially matched grafts from related donors. 13, 19 Our results differ in that we find no dependence of rejection on the source of graft. In addition, a study by Pawlowska et al 20 in pediatric ␤-thalassemia patients receiving HLAmatched sibling grafts after 14-16 mg/kg busulfan with 120-200 mg/kg cyclophosphamide did not find an association between graft rejection and busulfan AUC (rejection was observed in 5/64 patients). We observed no rejections with Bu Css Ͼ600 ng/ml regardless of donor recipient match.
In busulfan-and cyclophosphamide-containing regimens, three studies have reported a threshold for the development of severe RRT in adults with Bu Css Ͼ900-1000 ng/ml (which corresponds to an AUC of 1350-1500 M ϫ min). [11] [12] [13] An exception is the report on adult CML patients receiving HLA-matched sibling grafts following conditioning with 16 mg/kg busulfan and 120 mg/kg cyclophosphamide. In these patients there was no increased risk of Bone Marrow Transplantation toxicity with Bu Css Ͼ900 ng/ml. 7 Our results differ from these previous studies in that we observed severe RRT (Ͼgrade 2) in 2/31 evaluated patients with no dependence on Bu Css. The principal difference between our study and those just cited is that the dose of cyclophosphamide was higher in our pediatric patients than in adult patients in whom a relationship between Bu Css and RRT has been previously reported. Since only one of our patients had a Bu Css Ͼ900 ng/ml (this patient had a mean level of 2061 ng/ml and a grade 3 CNS RRT), we are unable to comment on the incidence of toxicity above this previously defined threshold. Our data suggest that higher Bu Css levels (Ͼ600 ng/ml) confer increased risk for RRT, but due to the small number of patients, statistical significance could not be established.
Vassal et al 8 conducted a study in 27 children with malignant tumors using busulfan 600 mg/m 2 , a dose felt to achieve AUCs comparable to adults receiving standard dose therapy (16 mg/kg). This was substantiated by the fact that extra-hematologic toxicities approached those seen in the adult population. The authors specifically found an increase in neurotoxicity from 1.7% to 15.4%. None of these patients received phenytoin prophylaxis. This, along with our observation of grade 3 neurotoxicity in four patients not receiving phenytoin, supports the need for seizure prophylaxis in all children receiving busulfan-containing conditioning regimens.
Tutschka et al 21 reported a decrease in the incidence of RRT when the total dose of cyclophosphamide was lowered to 120 mg/kg from 200 mg/kg in adults. In contrast, the study cited above by Pawlowska et al 20 where 27/64 patients received 120 mg/kg cyclophosphamide, severe RRT was observed at relatively low busulfan levels and there was no relationship between RRT and busulfan AUC.
In summary, we found that subjects with Bu Css Ͼ600 ng/ml have a high probability of engraftment, that grade 2 or higher toxicity does not appear to be related to Bu Css, and grade 3 or 4 toxicities may be related to Bu Css. Use of lower dose cyclophosphamide (120 mg/kg) may help decrease RRT while maintaining adequate immunosuppression. Our data support the use of targeted pharmacokinetic monitoring to maintain Bu Css above 600 ng/ml to maximize the rate of successful engraftment. The data also suggest that a trial of targeted Bu Css with lower cyclophosphamide doses is warranted.
